PLSE Receives IDE Approval to Begin nsPFA Cardiac Surgery Trial

Q: What did Pulse Biosciences (PLSE) announce in this 8-K?

The company announced the FDA granted an IDE to start the NANOCLAMP AF study of its nsPFA Cardiac Surgical System for treating atrial fibrillation.

Q: How large is the NANOCLAMP AF study described by PLSE?

The single-arm, prospective study plans to enroll up to 136 patients at up to 20 sites, including two sites outside the United States.

Q: Is the IDE approval itself an FDA clearance of the device?

No. The IDE approval permits the company to conduct a clinical study; it is not a marketing clearance or approval based on trial data.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Pulse Biosciences announced FDA approval of an Investigational Device Exemption (IDE) to begin a clinical study of its nsPFA Cardiac Surgical System for treating atrial fibrillation (AF). The approved NANOCLAMP AF study is a single-arm, prospective trial designed to show primary effectiveness when used in concomitant cardiac surgery. Up to 20 sites (including two outside the U.S.) are planned to enroll as many as 136 patients. The filing attaches a company press release and reiterates standard forward-looking statement cautions about clinical, regulatory, and technological risks.

Positive

FDA IDE approval granted to initiate the nsPFA Cardiac Surgical System study
Planned enrollment up to 136 patients, which is sizable for a device study
Multi-site plan (up to 20 sites) including two outside the U.S., supporting broader enrollment

Negative

Study is single-arm, limiting comparative evidence on effectiveness
No clinical outcome data yet; approval only permits study initiation
Forward-looking risks noted, including clinical, regulatory, and technological uncertainties

Insights

TL;DR: IDE approval enables clinical progress and may de-risk regulatory pathway, but no efficacy data yet.

The IDE approval is a milestone that allows Pulse to start a pivotal-style prospective study, which can materially advance the regulatory and commercial case if results are favorable. The planned scale (up to 136 patients, ~20 sites) is meaningful for a device-focused program and signals commitment to a surgical adoption pathway. Near-term value realization depends on enrollment pace, data readouts, and whether results demonstrate clear benefit over existing AF ablation tools.

TL;DR: Regulatory clearance to start an IDE trial is a key operational milestone but does not reflect clinical performance.

FDA IDE approval permits initiation of the NANOCLAMP AF trial, enabling systematic data collection in a controlled, single-arm design concurrent with cardiac surgery. The inclusion of international sites may broaden generalizability. However, a single-arm study limits comparative inference and the filing contains no clinical outcomes data; safety and effectiveness remain to be demonstrated through the trial.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Pulse Biosciences (PLSE) announce in this 8-K?

The company announced the FDA granted an IDE to start the NANOCLAMP AF study of its nsPFA Cardiac Surgical System for treating atrial fibrillation.

How large is the NANOCLAMP AF study described by PLSE?

The single-arm, prospective study plans to enroll up to 136 patients at up to 20 sites, including two sites outside the United States.

Does the 8-K include clinical results for the nsPFA Cardiac Surgical System?

No. The filing confirms IDE approval to initiate the study but contains no clinical outcome data.

What risks did Pulse Biosciences highlight in the filing?

The company included standard forward-looking statement cautions citing clinical, regulatory, and technological risks that could affect trial completion and outcomes.

Is the IDE approval itself an FDA clearance of the device?

No. The IDE approval permits the company to conduct a clinical study; it is not a marketing clearance or approval based on trial data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/08/2025 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 8, 2025

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On September 8, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had granted approval for the Company’s Investigational Device Exemption ("IDE"), allowing the Company to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation ("AF"). This single-arm, prospective study is designed to demonstrate primary effectiveness of the nsPFA Cardiac Surgical System for the treatment of AF in concomitant surgical procedures. Up to twenty sites, including two outside the United States, are planned to enroll up to 136 patients in the study.

A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding enrollment into the Company's IDE clinical trial of its nsPFA Cardiac Surgical System and whether the study can be completed successfully, and whether the study data will demonstrate the safety and effectiveness of the Company's nsPFA Cardiac Surgical System for the treatment of AF. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties, such as clinical, regulatory and technological risks, that could cause actual results to differ materially from those expressed or implied from such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description

99.1	Press Release issued by Pulse Biosciences, Inc. dated September 8, 2025 - Pulse Biosciences Announces FDA Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.


Date: September 8, 2025	By:	/s/ Paul A. LaViolette
		Paul LaViolette
		Chief Executive Officer (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR